Intas Pharmaceuticals Limited Pemetrexed Export Data — India (DGFT 2022–2026)

Name: Intas Pharmaceuticals Limited Pemetrexed Export Records India — #6 Exporter, 28 Shipments, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Pemetrexed

India Pharmaceutical Trade Intelligence

$28.8M138 Suppliers92 CountriesHS 30049049

ExportsIndia → GERMANY30.1%India → UNITED STATES26.8%

ImportsFRANCE → India$36.6M SOUTH KOREA → India$147.9K

#1 Supplier: FRESENIUS KABI #1 Buyer: FRESENIUS KABI

Intas Pharmaceuticals Limited — Pemetrexed Exporter #6 | $1.4M Trade Value | TransData Nexus | TransData Nexus

Intas Pharmaceuticals Limited — Pemetrexed Exporter Profile

Indian Pharmaceutical Exporter · #6 for Pemetrexed · $1.4M export value · DGFT Verified

Intas Pharmaceuticals Limited is the #6 Indian exporter of Pemetrexed with $1.4M in export value and 28 verified shipments. Intas Pharmaceuticals Limited holds a 4.8% market share in Pemetrexed exports across 11 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.

Intas Pharmaceuticals Limited — Pemetrexed Export Profile: Buyers & Destinations

Intas Pharmaceuticals Limited Pemetrexed export treemap — buyers and destination countries | TransData Nexus

Where Does Intas Pharmaceuticals Limited Export Pemetrexed?

Country	Value	Shipments	Share
CANADA	$176.3K	4	25.3%
FRANCE	$150.0K	3	21.5%
AUSTRALIA	$150.0K	3	21.5%
SOUTH AFRICA	$50.0K	1	7.2%
SWITZERLAND

Who Are the Top Buyers of Pemetrexed from Intas Pharmaceuticals Limited?

Buyer	Country	Value	Orders
XXCORXXHEAXXHCAXX B XX	NETHERLANDS	$162.2K	5
XXCORXXHEAXXHCAXX PTXXLIMITED	AUSTRALIA	$100.0K	2
XXCORXXHEAXXHCAXX INXX	CANADA	$98.0K	2
ACCORD HEALTHCARE INC	CANADA	$78.4K	2
XXCORXXHEAXXHCAXX(PTXXLIMITED	SOUTH AFRICA	$50.0K	1
ACCORD HEALTHCARE PTY LIMITED	AUSTRALIA	$50.0K	1
ACCORD HEALTHCARE POLSKA SP Z O O	POLAND	$30.6K	1
XXCORXXHEAXXHCAXX AG	SWITZERLAND	$19.7K	1
ACCORD HEALTHCARE AG	SWITZERLAND	$19.7K	1
XXCORXXHEAXXHCAXX SXX	SPAIN	$18.4K	1

Intas Pharmaceuticals Limited supplies Pemetrexed to 22 buyers globally. The largest buyer is XXCORXXHEAXXHCAXX B XX (NETHERLANDS), followed by XXCORXXHEAXXHCAXX PTXXLIMITED (AUSTRALIA) and XXCORXXHEAXXHCAXX INXX (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Pemetrexed Formulations Does Intas Pharmaceuticals Limited Export?

Product Description / Formulation	Value	Shipments
PEMETREXED ACCORD 1000MG 1X1V AUS	$150.0K	3
PEMETREXED RTU 25MG/ML 20ML(ACO-FRANCE	$102.8K	3
PEMETREXED DISODIUM 500 MG/VIAL	$50.0K	1
PEMETREXEDACCORD 500MG/VIAL LYO.1V	$50.0K	1
ACCORD PEMETREXED25MG/ML,40ML1VP1 AC-CAN	$50.0K	1
PEMETREXED RTU 25MG/ML20MLACO-FRANCE	$50.0K	1
PEMETREXED DISODIUM 100 MG/VIAL	$48.0K	1
PEMETREXED RTU 25MG/ML,4MLACCO-SLOVENIA	$30.6K	1
ACCORD PEMETREXED 25MG/ML,20ML 1V AC-CAN	$28.4K	1
PEMETREXED RTU25MG/ML40ML P1(ACO-SWITZER	$19.7K	1

Intas Pharmaceuticals Limited exports 24 distinct Pemetrexed formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PEMETREXED ACCORD 1000MG 1X1V AUS with 3 shipments worth $150.0K.

How Does Intas Pharmaceuticals Limited Compare to Nearest Pemetrexed Exporters?

Exporters ranked immediately above and below #6 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
4	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$2.0M	64	8	$31.6K
5	RELIANCE LIFE SCIENCES PRIVATE LIMITED	$2.0M	52	11	$38.5K
6	INTAS PHARMACEUTICALS LIMITED ★	$1.4M	28	11	$49.7K
8	NAPROD LIFE SCIENCES PRIVATE LIMITED	$812.5K	32	3	$25.4K
9	VENUS REMEDIES LIMITED	$507.2K	42	8	$12.1K

Intas Pharmaceuticals Limited ranks #6 among 138 Indian Pemetrexed exporters. Average shipment value of $49.7K compared to the market average of $145.0K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and RELIANCE LIFE SCIENCES PRIVATE LIMITED.

Which Indian Ports Ship Pemetrexed Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	209	17.3%
SAHAR AIR CARGO ACC (INBOM4)	181	15.0%
SAHAR AIR	163	13.5%
DELHI AIR	133	11.0%
CHAWAPAYAL ICD	43	3.6%
CHAWAPAYAL ICD (INCPR6)	41	3.4%
Bombay Air	33	2.7%
HYDERABAD AIR	32	2.6%

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Pemetrexed Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)

Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Pemetrexed shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 34 individual customs records matching Intas Pharmaceuticals Limited exporting Pemetrexed, covering 24 formulations to 13 countries via 22 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 92+ countries, 309+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Pemetrexed

Pemetrexed

Intas Pharmaceuticals Limited — Pemetrexed Exporter Profile

Intas Pharmaceuticals Limited — Pemetrexed Export Profile: Buyers & Destinations

Where Does Intas Pharmaceuticals Limited Export Pemetrexed?

Who Are the Top Buyers of Pemetrexed from Intas Pharmaceuticals Limited?

What Is India's Total Pemetrexed Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?

What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Pemetrexed Exports?

How Does Intas Pharmaceuticals Limited Compare to Other Indian Pemetrexed Exporters?

What Pemetrexed Formulations Does Intas Pharmaceuticals Limited Export?

Regulatory Requirements: Exporting Pemetrexed to Key Markets

Canada — HC

Australia — TGA

How Does Intas Pharmaceuticals Limited Compare to Nearest Pemetrexed Exporters?

Which Indian Ports Ship Pemetrexed Exports?

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Pemetrexed Exports

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

About Intas Pharmaceuticals Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Pemetrexed Export Data from Intas Pharmaceuticals Limited

Pemetrexed Stats

Company Overview

Top Products by Intas Pharmaceuticals Limited

Related Analysis

Need Detailed Export Data?

Data Source